Discontinued — last reported Q4 '25
Investing
Acquisitions
Year-over-year, this metric declined by 105.9%, from $237.00M to -$14.00M.
Analysis
StatementCash Flow Statement
SectionInvesting
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ1 2013
Last reportedQ4 2025
How to read this metric
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
Detailed definition
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Peer comparison
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
Metric ID:
cf_acquisitionsHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $7.00M | $7.00M | $7.00M | $7.00M | $0.00 | $0.00 | $0.00 | $246.00M | $622.00M | $0.00 | $0.00 | $0.00 | $237.00M | $0.00 | $3.08B | $0.00 | -$14.00M |
| QoQ Change | — | — | — | — | +0.0% | +0.0% | +0.0% | -100.0% | — | — | — | +152.8% | -100.0% | — | — | — | -100.0% | — | -100.0% | — |
| YoY Change | — | — | — | — | — | — | — | -100.0% | -100.0% | -100.0% | >999% | — | — | — | -100.0% | -61.9% | — | — | — | -105.9% |
Range-$14.00M – $3.08B
Avg YoY Growth+406.6%
Median YoY Growth-100.0%
Current Streak2+ quarters decline
Acquisitions at Other Companies
Frequently Asked Questions
- What is MPLX's acquisitions?
- MPLX (MPLX) reported acquisitions of -$14.00M in Q1 2026.
- How has MPLX's acquisitions changed year-over-year?
- MPLX's acquisitions decreased by 105.9% year-over-year, from $237.00M to -$14.00M.
- What does acquisitions mean?
- Cash spent to acquire other companies or businesses, net of cash received in the deal.